Table 3 Relationship between wild-type full-length p53 mRNA expression level and clinical, pathological and biological factors
wild-type full-length p53 RNA level | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Q1 (<25%) | Q2 & Q3 (25–75%) | Q4 (>75%) | |||||||||
Characteristic | Total No. | Total (%) | No. of patients | (%) | No. of patients | (%) | No. of patients | (%) | Groups | p | |
Estrogen receptor status | Negative | 10 | 20 | 4 | 30.8 | 1 | 4.2 | 5 | 38.5 | Q1-Q2/3-Q4 1 | p < 0.03 |
Positive | 40 | 80 | 9 | 69.2 | 23 | 95.8 | 8 | 61.5 | Q1-Q2/32 | p < 0.03 | |
Q1-Q42 | n.s. | ||||||||||
Q2/3-Q42 | p < 0.009 | ||||||||||
Progesterone receptor status | Negative | 13 | 26 | 3 | 23.1 | 3 | 12.5 | 7 | 53.8 | Q1-Q2/3-Q4 1 | p < 0.03 |
Positive | 37 | 74 | 10 | 76.9 | 21 | 87.5 | 6 | 46.2 | Q1-Q2/32 | n.s. | |
Q1-Q42 | n.s. | ||||||||||
Q2/3-Q42 | p < 0.009 | ||||||||||
ERBB2/HER status | Negative | 29 | 80.6 | 9 | 75.0 | 13 | 86.7 | 7 | 77.8 | Q1-Q2/3-Q4 1 | n.s. |
Positive | 7 | 19.4 | 3 | 25.0 | 2 | 13.3 | 2 | 22.2 | Q1-Q2/32 | n.s. | |
Q1-Q42 | n.s. | ||||||||||
Q2/3-Q42 | n.s. | ||||||||||
Grade | 1 | 5 | 10.0 | 0 | 0.0 | 2 | 8.3 | 3 | 23.1 | Q1-Q2/3-Q4 1 | p < 0.003 |
2 | 24 | 48.0 | 2 | 15.4 | 15 | 62.5 | 7 | 53.8 | Q1-Q2/32 | p < 0.003 | |
3 | 21 | 42.0 | 11 | 84.6 | 7 | 29.2 | 3 | 23.1 | Q1-Q42 | p < 0.003 | |
Q2/3-Q42 | n.s. | ||||||||||
Subgroups | Luminal A | 25 | 53.2 | 1 | 9.1 | 18 | 75.0 | 6 | 50.0 | Q1-Q2/3-Q4 1 | p < 0.007 |
Luminal B | 6 | 12.8 | 3 | 27.3 | 0 | 0.0 | 3 | 25.0 | Q1-Q2/32 | p < 0.003 | |
ERBB2 | 7 | 14.9 | 3 | 27.3 | 3 | 12.5 | 1 | 8.3 | Q1-Q42 | p < 0.05 | |
Basal | 4 | 8.5 | 2 | 18.2 | 1 | 4.2 | 1 | 8.3 | Q2/3-Q42 | n.s. | |
Normal-like | 5 | 10.6 | 2 | 18.2 | 2 | 8.3 | 1 | 8.3 | |||